Main Menu

Top drugs company relocates to Scotland

Biotech firm quits south for Dundee’s life sciences cluster

Cellexus(Updated) Dundee’s growing reputation as a centre of excellence in life sciences has persuaded a company from Cambridgeshire to relocate its operations to the town.

Cellexus said it was influenced by Dundee’s collaborative links with the University of Dundee and the NHS together with the availability of support for life sciences companies.

It now aims to expand its range of products and tap into new overseas markets. The company will receive up to £250,000 from the Scottish Investment Bank, an arm of Scottish Enterprise, to make the move and to support its global sales and marketing ambitions.

The company has appointed a business development manager whose task will be to set up a distributor network to sell its products in the various bio tech hot spots in the world. It is recruiting someone to develop its digital media content.

There are currently four staff and it expects to have seven by the end of this year and 12 by the end of 2016 if sales targets are met.

No staff came up from Cambridgeshire but one has been retained as a consultant. Companies were helped with the moving of production to Dundee by Albacom.

Julia Brown, director of life and chemical sciences at Scottish Enterprise, said: “That Cellexus has chosen to move to Dundee from Cambridgeshire is testament to Scotland’s reputation as the location of choice for life sciences companies. Cellexus is an innovative, forward-thinking company and we look forward to continuing to work with them to help them successfully up-scale and explore new markets, driving forward their ambitious growth plan.”

Bob Cumming, director, Cellexus, said: “Coming to Dundee has enabled Cellexus to join the vibrant life sciences sector in Scotland and we have been most impressed by the help and assistance we have had from the various departments in Scottish Enterprise”

The company’s products have been sold in UK, Ireland, Germany, Poland and US. Turnover is expected to reach £2 million in 2016 as increases by 15-20% per annum until 2021.

Cellexus uses a system to produce proteins from bacteria such as yeast, ecoli and algae. These proteins are then used in foods, diagnostics, biofuels and pharmaceuticals – 71% of the top ten drugs used in the world are made by biotechnological processes.

News of the move comes a week before the 15th annual Scottish Enterprise Life Sciences Awards. Held at the International Conference Centre in Edinburgh on 5 February, the event recognises the achievements of individuals, companies and research organisations within the Scottish life sciences industry.

Share The News Tweet about this on TwitterShare on FacebookShare on Google+Email this to someoneShare on LinkedIn





Leave a Reply

Your email address will not be published. Required fields are marked as *

*